Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

masaki shiota, Akira Yokomizo, Masatoshi Eto

Research output: Contribution to journalShort survey

11 Citations (Scopus)

Abstract

Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. However, the prognosis of men with CRPC is still poor. The duration from initiation of ADT to CRPC has not improved in recent decades because no novel therapeutic options have emerged. However, recently, up-front docetaxel chemotherapy has been shown to prolong progression-free as well as overall survival in men with metastatic hormone-naïve prostate cancer. This offers a new way to expand the role of chemotherapy for hormone-naïve prostate cancer. In this review, we summarize the proof-of-concept as well as the current status of taxane chemotherapy for hormone-naïve prostate cancer, focusing on phase 3 clinical trials investigating oncological outcome, and discuss the future direction in this field.

Original languageEnglish
Article number304
JournalFrontiers in Oncology
Volume5
Issue numberJAN
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Prostatic Neoplasms
Hormones
Drug Therapy
docetaxel
Castration
Androgens
Taxoids
Phase III Clinical Trials
taxane
Androgen Receptors
Therapeutics
Clinical Trials
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy. / shiota, masaki; Yokomizo, Akira; Eto, Masatoshi.

In: Frontiers in Oncology, Vol. 5, No. JAN, 304, 01.01.2016.

Research output: Contribution to journalShort survey

@article{35666341660a46c3a8d387e97a174c56,
title = "Taxane chemotherapy for hormone-na{\"i}ve prostate cancer with its expanding role as breakthrough strategy",
abstract = "Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. However, the prognosis of men with CRPC is still poor. The duration from initiation of ADT to CRPC has not improved in recent decades because no novel therapeutic options have emerged. However, recently, up-front docetaxel chemotherapy has been shown to prolong progression-free as well as overall survival in men with metastatic hormone-na{\"i}ve prostate cancer. This offers a new way to expand the role of chemotherapy for hormone-na{\"i}ve prostate cancer. In this review, we summarize the proof-of-concept as well as the current status of taxane chemotherapy for hormone-na{\"i}ve prostate cancer, focusing on phase 3 clinical trials investigating oncological outcome, and discuss the future direction in this field.",
author = "masaki shiota and Akira Yokomizo and Masatoshi Eto",
year = "2016",
month = "1",
day = "1",
doi = "10.3389/fonc.2015.00304",
language = "English",
volume = "5",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

AU - shiota, masaki

AU - Yokomizo, Akira

AU - Eto, Masatoshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. However, the prognosis of men with CRPC is still poor. The duration from initiation of ADT to CRPC has not improved in recent decades because no novel therapeutic options have emerged. However, recently, up-front docetaxel chemotherapy has been shown to prolong progression-free as well as overall survival in men with metastatic hormone-naïve prostate cancer. This offers a new way to expand the role of chemotherapy for hormone-naïve prostate cancer. In this review, we summarize the proof-of-concept as well as the current status of taxane chemotherapy for hormone-naïve prostate cancer, focusing on phase 3 clinical trials investigating oncological outcome, and discuss the future direction in this field.

AB - Historically, androgen-deprivation therapy (ADT) was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. However, the prognosis of men with CRPC is still poor. The duration from initiation of ADT to CRPC has not improved in recent decades because no novel therapeutic options have emerged. However, recently, up-front docetaxel chemotherapy has been shown to prolong progression-free as well as overall survival in men with metastatic hormone-naïve prostate cancer. This offers a new way to expand the role of chemotherapy for hormone-naïve prostate cancer. In this review, we summarize the proof-of-concept as well as the current status of taxane chemotherapy for hormone-naïve prostate cancer, focusing on phase 3 clinical trials investigating oncological outcome, and discuss the future direction in this field.

UR - http://www.scopus.com/inward/record.url?scp=84958213594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958213594&partnerID=8YFLogxK

U2 - 10.3389/fonc.2015.00304

DO - 10.3389/fonc.2015.00304

M3 - Short survey

AN - SCOPUS:84958213594

VL - 5

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JAN

M1 - 304

ER -